VYRSA built a three-product answer to a stubborn source of back pain, won FDA clearance for a stranger kind of implant, and sold to Nevro before its third birthday. The playbook is compact: license hard science, simplify the procedure, and let a bigger sales force carry it.
It sells peace of mind to working parents, a business to local owners, and a play-based curriculum to nearly 100,000 kids. Inside the franchise that turned early childhood into one of America's most resilient service industries.